{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:32:29Z","timestamp":1784752349640,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.breast.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:21:53Z","timestamp":1616066513000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab"],"prefix":"10.1016","volume":"57","author":[{"given":"Rita","family":"De Sanctis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3966-1984","authenticated-orcid":false,"given":"Arianna","family":"Marinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Masci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5674-9350","authenticated-orcid":false,"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Zuradelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2021.03.004_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2021.03.004_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2021.03.004_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"Herceptin Adjuvant (HERA) Trial Study Team. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2021.03.004_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-018-4967-8","article-title":"Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials","volume":"173","author":"Niraula","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.03.004_bib5","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.breast.2021.03.004_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11886-019-1121-0","article-title":"Cardiotoxicity of targeted cancer drugs: concerns, \"the cart before the horse,\" and lessons from trastuzumab","volume":"21","author":"Menna","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.breast.2021.03.004_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000659","article-title":"Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials","volume":"5","author":"Eiger","year":"2020","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.breast.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2021.03.004_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2021.03.004_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.03.087","article-title":"HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up","volume":"62","author":"Jackisch","year":"2016","journal-title":"Eur J Canc"},{"issue":"Suppl 7","key":"10.1016\/j.breast.2021.03.004_bib11","article-title":"ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2021.03.004_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10549-020-05930-w","article-title":"Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study","volume":"185","author":"Jacobse","year":"2021","journal-title":"Breast Canc Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00392-019-01417-x","article-title":"Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer","volume":"108","author":"Yoon","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"33","key":"10.1016\/j.breast.2021.03.004_bib14","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2021.03.004_bib15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2021.03.004_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2019.10.002","article-title":"Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: the French HERmione non-interventional prospective study","volume":"49","author":"Jacquin","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.breast.2021.03.004_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","article-title":"A\u00a0real-world study of cardiac events in >\u20093700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study","volume":"174","author":"Lidbrink","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.03.004_bib18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2021.03.004_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2021.03.004_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4048\/jbc.2014.17.4.363","article-title":"Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study","volume":"17","author":"Xue","year":"2014","journal-title":"J\u00a0Breast Cancer"},{"key":"10.1016\/j.breast.2021.03.004_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1389200216888150915112039","article-title":"Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines","volume":"16","author":"Edwardson","year":"2015","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.breast.2021.03.004_bib22","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2021.03.004_bib23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41416-018-0057-2","article-title":"First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study","volume":"118","author":"Haug","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2021.03.004_bib24","article-title":"Epidemiology of breast cancer, a paradigm of the \"common soil\" hypothesis","author":"Iacoviello","year":"2020","journal-title":"Semin Canc Biol"},{"key":"10.1016\/j.breast.2021.03.004_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0339","article-title":"Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial","volume":"5","author":"Jackisch","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2021.03.004_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/annonc\/mdu524","article-title":"Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study","volume":"26","author":"Jackisch","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2021.03.004_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2017.08.019","article-title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","volume":"86","author":"Pivot","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2021.03.004_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.05.010","article-title":"Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study\u2019s primary analysis of 2573 patients","volume":"82","author":"Gligorov","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2021.03.004_bib29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CRD.0000000000000252","article-title":"The preventive role of angiotensin converting enzyme inhibitors\/angiotensin-II receptor blockers and \u03b2-adrenergic blockers in anthracycline- and trastuzumab-induced cardiotoxicity","volume":"27","author":"Blanter","year":"2019","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.breast.2021.03.004_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2021.03.004_bib31","series-title":"Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study","author":"Tan","year":"2019"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762100343X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762100343X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:48:51Z","timestamp":1783943331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762100343X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"alternative-id":["S096097762100343X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.03.004","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}